<a href="https://www.fiercebiotech.com/biotech/asco-lilly-debuts-bladder-cancer-data-potential-padcev-challenger" hreflang="en">ASCO: Lilly debuts ‘strong’ bladder cancer data for potential Padcev challenger</a>
Eli Lilly presented promising early data for its new bladder cancer drug, LY4052031, at the ASCO 2026 conference, which could potentially rival Pfizer and Astellas' Padcev. The drug, an antibody-drug conjugate targeting Nectin-4, showed a 42% tumor shrinkage rate in evaluated patients, including those previously treated with Padcev, though some patients experienced severe side effects due to genetic factors.
Eli Lilly's early phase 1 trial results for their new ADC, LY4052031, show promising tumor shrinkage in 42% of patients with advanced bladder cancer, including those previously treated with Padcev and Keytruda. This suggests that LY4052031, which uses a novel topoisomerase I inhibitor payload, could potentially compete in first-line treatments, contingent upon successful further trials and addressing genetic predispositions to adverse effects.